> top > docs > PMC:7204657 > spans > 68-2125 > annotations

PMC:7204657 / 68-2125 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
22 82-86 Gene denotes IL-6 Gene:3569
23 245-253 Species denotes patients Tax:9606
24 680-688 Species denotes patients Tax:9606
25 847-855 Species denotes patients Tax:9606
26 51-62 Chemical denotes tocilizumab MESH:C502936
27 194-205 Chemical denotes tocilizumab MESH:C502936
28 362-373 Chemical denotes Tocilizumab MESH:C502936
29 529-540 Chemical denotes tocilizumab MESH:C502936
30 762-773 Chemical denotes tocilizumab MESH:C502936
31 866-877 Chemical denotes tocilizumab MESH:C502936
32 175-183 Disease denotes COVID-19 MESH:C000657245
33 236-244 Disease denotes COVID-19 MESH:C000657245
34 434-454 Disease denotes rheumatoid arthritis MESH:D001172
35 459-479 Disease denotes giant cell arteritis MESH:D013700
36 594-612 Disease denotes infectious disease MESH:D003141
37 656-670 Disease denotes critically ill MESH:D016638
38 671-679 Disease denotes COVID-19 MESH:C000657245
39 913-927 Disease denotes diverticulitis MESH:D004238
49 1006-1037 Gene denotes angiotensin-converting enzyme 2 Gene:59272
50 1039-1043 Gene denotes ACE2 Gene:59272
51 1150-1154 Gene denotes ACE2 Gene:59272
52 969-974 Species denotes human Tax:9606
53 992-1002 Species denotes SARS-CoV-2 Tax:2697049
54 1209-1219 Species denotes SARS-CoV-2 Tax:2697049
55 1167-1192 Disease denotes gastrointestinal symptoms MESH:D012817
56 1253-1278 Disease denotes gastrointestinal symptoms MESH:D012817
57 1288-1302 Disease denotes abdominal pain MESH:D015746
67 1881-1899 Gene denotes C-reactive protein Gene:1401
68 1901-1904 Gene denotes CRP Gene:1401
69 1393-1401 Species denotes patients Tax:9606
70 1973-1981 Species denotes patients Tax:9606
71 1643-1654 Chemical denotes tocilizumab MESH:C502936
72 1771-1782 Chemical denotes tocilizumab MESH:C502936
73 1369-1383 Disease denotes critically ill MESH:D016638
74 1384-1392 Disease denotes COVID-19 MESH:C000657245
75 1667-1675 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T2 96-104 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T3 126-134 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T4 465-469 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T5 775-785 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T6 821-831 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T7 1079-1089 Body_part denotes intestines http://purl.org/sig/ont/fma/fma7199
T8 1095-1105 Body_part denotes Intestinal http://purl.org/sig/ont/fma/fma7199
T9 1220-1223 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T10 1456-1466 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T11 1501-1511 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T12 1615-1625 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T13 1820-1830 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T14 1892-1899 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 1079-1089 Body_part denotes intestines http://purl.obolibrary.org/obo/UBERON_0000160

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T3 175-183 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 236-244 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 434-454 Disease denotes rheumatoid arthritis http://purl.obolibrary.org/obo/MONDO_0008383
T6 445-454 Disease denotes arthritis http://purl.obolibrary.org/obo/MONDO_0005578
T7 459-479 Disease denotes giant cell arteritis http://purl.obolibrary.org/obo/MONDO_0008538
T8 470-479 Disease denotes arteritis http://purl.obolibrary.org/obo/MONDO_0043494
T9 594-612 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T10 671-679 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T11 775-797 Disease denotes intestinal perforation http://purl.obolibrary.org/obo/MONDO_0006807
T12 821-843 Disease denotes intestinal perforation http://purl.obolibrary.org/obo/MONDO_0006807
T13 913-927 Disease denotes diverticulitis http://purl.obolibrary.org/obo/MONDO_0004235
T14 992-1000 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T15 1209-1217 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T16 1384-1392 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T17 1615-1637 Disease denotes intestinal perforation http://purl.obolibrary.org/obo/MONDO_0006807
T18 1667-1675 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T19 1820-1842 Disease denotes intestinal perforation http://purl.obolibrary.org/obo/MONDO_0006807

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T3 64-65 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 259-260 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 465-469 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T6 728-729 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 775-785 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T8 775-785 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T9 821-831 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T10 821-831 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T11 928-931 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T12 946-947 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T13 969-974 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T14 1079-1089 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestines
T15 1079-1089 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestines
T16 1095-1105 http://purl.obolibrary.org/obo/UBERON_0000160 denotes Intestinal
T17 1095-1105 http://www.ebi.ac.uk/efo/EFO_0000834 denotes Intestinal
T18 1456-1466 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T19 1456-1466 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T20 1501-1511 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T21 1501-1511 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T22 1615-1625 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T23 1615-1625 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T24 1820-1830 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T25 1820-1830 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 51-62 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T2 82-84 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T4 194-205 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T5 529-540 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T6 762-773 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T7 866-877 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T8 1006-1017 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T9 1643-1654 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T10 1771-1782 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T11 1892-1899 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T12 2055-2057 Chemical denotes NA http://purl.obolibrary.org/obo/CHEBI_33696

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 1106-1123 http://purl.obolibrary.org/obo/GO_0019079 denotes viral replication
T2 1106-1123 http://purl.obolibrary.org/obo/GO_0019058 denotes viral replication
T3 1798-1818 http://purl.obolibrary.org/obo/GO_0006953 denotes acute phase response

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T3 0-12 Sentence denotes Dear Editor,
T4 13-184 Sentence denotes Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19.
T5 185-361 Sentence denotes Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown.
T6 362-480 Sentence denotes Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis.
T7 481-689 Sentence denotes Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients.
T8 690-802 Sentence denotes Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2].
T9 803-964 Sentence denotes The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2].
T10 965-1094 Sentence denotes The human host receptor of SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2), which is highly expressed in the intestines [3].
T11 1095-1247 Sentence denotes Intestinal viral replication is likely considering the ACE2 expression, gastrointestinal symptoms and presence of SARS-CoV-2 RNA in fecal samples [4,5].
T12 1248-1355 Sentence denotes Some gastrointestinal symptoms, such as abdominal pain, are associated with increased disease severity [5].
T13 1356-1530 Sentence denotes Furthermore, critically ill COVID-19 patients may have altered hemodynamics, potentially leading to intestinal hypoperfusion that can compromise intestinal mucosal integrity.
T14 1531-1759 Sentence denotes More studies are required to evaluate whether these variables influence the risk of intestinal perforation with tocilizumab in critical COVID-19 cases; however, clinicians should be aware of the potential for this adverse event.
T15 1760-1982 Sentence denotes Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevation and may initially go unnoticed in sedated and ventilated patients.
T16 1984-1996 Sentence denotes Declarations
T17 1997-2005 Sentence denotes Funding:
T18 2006-2010 Sentence denotes None
T19 2011-2031 Sentence denotes Competing Interests:
T20 2032-2036 Sentence denotes None
T21 2037-2057 Sentence denotes Ethical Approval: NA

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T2 126-151 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T3 434-454 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T4 470-479 Phenotype denotes arteritis http://purl.obolibrary.org/obo/HP_0012089
T5 775-797 Phenotype denotes intestinal perforation http://purl.obolibrary.org/obo/HP_0031368
T6 821-843 Phenotype denotes intestinal perforation http://purl.obolibrary.org/obo/HP_0031368
T7 1288-1302 Phenotype denotes abdominal pain http://purl.obolibrary.org/obo/HP_0002027
T8 1615-1637 Phenotype denotes intestinal perforation http://purl.obolibrary.org/obo/HP_0031368
T9 1798-1818 Phenotype denotes acute phase response http://purl.obolibrary.org/obo/HP_0033331
T10 1820-1842 Phenotype denotes intestinal perforation http://purl.obolibrary.org/obo/HP_0031368